These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 26033434)

  • 21. Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential.
    Bayo J; Dalvi MP; Martinez ED
    Future Med Chem; 2015; 7(16):2243-61. PubMed ID: 26510529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic therapy for solid tumors: from bench science to clinical trials.
    Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
    Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer.
    Stazi G; Fioravanti R; Mai A; Mattevi A; Valente S
    Curr Opin Chem Biol; 2019 Jun; 50():89-100. PubMed ID: 30986654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems.
    Garmpi A; Garmpis N; Damaskos C; Valsami S; Spartalis E; Lavaris A; Patelis N; Margonis GA; Apostolou KG; Spartalis M; Andreatos N; Diamantis E; Tsivelekas K; Moschos MM; Nonni A; Tsourouflis G; Markatos K; Antoniou EA; Kontzoglou K; Nikiteas N; Dimitroulis D
    J BUON; 2018; 23(4):846-861. PubMed ID: 30358185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenome-based personalized medicine in human cancer.
    Yan W; Herman JG; Guo M
    Epigenomics; 2016 Jan; 8(1):119-33. PubMed ID: 26344672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy.
    Wu J; Nie J; Luan Y; Ding Y
    Curr Med Chem; 2023; 30(20):2267-2311. PubMed ID: 36043742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylases and epigenetic therapies of hematological malignancies.
    Mercurio C; Minucci S; Pelicci PG
    Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitors: a patent review (2009 - 2011).
    Carafa V; Miceli M; Altucci L; Nebbioso A
    Expert Opin Ther Pat; 2013 Jan; 23(1):1-17. PubMed ID: 23094822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
    Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
    Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New patented histone deacetylase inhibitors.
    Wang H; Dymock BW
    Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors for cancer therapy.
    Kim TY; Bang YJ; Robertson KD
    Epigenetics; 2006; 1(1):14-23. PubMed ID: 17998811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
    Ali SR; Humphreys KJ; McKinnon RA; Michael MZ
    Drug Dev Res; 2015 Sep; 76(6):296-317. PubMed ID: 26303212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting triple negative breast cancer with histone deacetylase inhibitors.
    Fedele P; Orlando L; Cinieri S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promising strategies: Combination of epigenetic inhibitors for cancer therapy.
    Gronemeyer H
    Int J Cancer; 2020 Nov; 147(10):2656-2657. PubMed ID: 32599650
    [No Abstract]   [Full Text] [Related]  

  • 38. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.
    Shen L; Orillion A; Pili R
    Epigenomics; 2016 Mar; 8(3):415-28. PubMed ID: 26950532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
    Feng W; Zhang B; Cai D; Zou X
    Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic therapy of lymphoma using histone deacetylase inhibitors.
    Cotto M; Cabanillas F; Tirado M; García MV; Pacheco E
    Clin Transl Oncol; 2010 Jun; 12(6):401-9. PubMed ID: 20534395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.